Santiago Escrivá-de-Romaní

TL;DR: The SOPHIA phase 3 randomized open-label trial of margetuximab vs trastuzumab, each with chemotherapy, in patients with pretreated ERBB2-positive advanced breast cancer (ABC) remains typically incurable with optimal treatment undefined in later lines of therapy as discussed by the authors.

TL;DR: New strategies in development to treat HER2-positive metastatic breast cancer referring to the mechanisms of action of new drugs and new combinations including results reported so far are examined.

TL;DR: Pretreated HER2+ MBC lacks a defined standard of care, although T is commonly used, and M has similar HER2 binding and antiproliferative effects as T, but by contrast, M’s Fc region is significantly different from T.

TL;DR: It is shown that p95HER2 is not expressed in normal tissues, paving the way for the safe treatment of a subgroup of HER2-positive tumors by targeting a tumor-specific antigen.